Physician profile
Marc A Kates
NPI 1326044025
$9,425.09
in general payments reported to CMS, 2019-2025
34 companies · $1,257 in 2025
The $1,257 reported for 2025 was more than what 75% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,414 · 2020: $497 · 2021: $1,347 · 2022: $2,236 · 2023: $1,471 · 2024: $1,202 · 2025: $1,257.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,930.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,930.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,148.67 | 2019-2025 | |
| Amgen INC. | $999.07 | 2019-2024 | Repatha |
| E.R. Squibb & Sons, L.L.C. | $954.97 | 2019-2025 | Camzyos, Eliquis |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $850.89 | 2019-2025 | Lifevest |
| Edwards Lifesciences Corporation | $821.17 | 2022-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Medtronic, INC. | $676.80 | 2021-2025 | Cobalt Dr Mri Surescan, Venaseal |
| Pfizer INC. | $563.19 | 2019-2025 | |
| Abbott Laboratories | $456.07 | 2019-2025 | Triclip |
| Janssen Pharmaceuticals, INC | $413.76 | 2019-2023 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $410.24 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $299.53 | 2019-2025 | Farxiga |
| Kestra Medical Technology Services, INC. | $234.67 | 2022-2025 | Assure Wcd |
| Amarin Pharma, INC. | $208.15 | 2019-2021 | |
| Alnylam Pharmaceuticals INC. | $180.63 | 2023-2025 | Amvuttra |
| Merck Sharp & Dohme LLC | $175.24 | 2021-2025 | Verquvo |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Impulse Dynamics (USA) INC. | $130.20 | 2022 | |
| Cleerly, INC. | $108.61 | 2025 | Cleerly Labs, Cleerly Ischemia |
| Astellas Pharma US INC | $88.64 | 2019-2021 | |
| Boston Scientific Corporation | $87.88 | 2021 | |
| Sanofi-Aventis U.S. LLC | $80.27 | 2022-2023 | |
| Actelion Pharmaceuticals US, INC. | $78.44 | 2019-2025 | Opsumit |
| Regeneron Healthcare Solutions, INC. | $71.61 | 2019 | |
| Chiesi USA, INC. | $60.02 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $55.36 | 2021-2025 | |
| Penumbra, INC. | $49.21 | 2024 | Indigo System |
| Medtronic Vascular, INC. | $45.81 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $38.41 | 2024 | |
| Kiniksa Pharmaceuticals International, Plc | $32.56 | 2024 | Arcalyst |
| Bardy Diagnostics, INC. | $30.00 | 2022 | |
| Aegerion Pharmaceuticals, INC. | $19.17 | 2019 | |
| Cvrx, INC. | $15.97 | 2023 | Barostim Neo System |
| Kiniksa Pharmaceuticals, LTD. | $14.55 | 2022 | |
| Esperion Therapeutics, INC. | $13.04 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $12.29 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marc Kates listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.